AG Schönermarck
Dr. Ulf Schönermarck MD
Medizinische Klinik und Poliklinik IV
Nephrologisches Zentrum LMU Klinikum - Campus Großhadern
81377 Munich, Germany
Ulf Schönermarck is a Nephrologist at the University Hospital Munich, Germany. His clinical and research interests focus on diagnosis, treatment and outcome of systemic diseases with renal involvement including ANCA-associated vasculitides and thrombotic microangiopathies. He is also interested in improving clinical collaboration with laboratory medicine and pharmacology.
Qualifications
- Medical Specialist for Internal Medicine (Facharzt für Innere Medizin)
- Medical Specialist for Nephrology (Anerkennung als Nephrologe)
Biography
Ulf Schönermarck, MD, is a Nephrologist at the University Hospital Munich, Ludwig-Maximilians-University, Germany.
He received his medical degree from the Martin-Luther-University Halle-Wittenberg. After starting his training in Internal Medicine at the Rheumaklinik Bad Bramstedt / Department of Rheumatology of the Medical University of Lübeck, he completed his training in Internal Medicine and Nephrology in the University Hospital Munich.
His interests focus on immunopathology and treatment of systemic diseases with renal involvement including ANCA-associated vasculitides and thrombotic micrangiopathies (TTP/aHUS) as well as transplant nephrology.
Teaching
- MECUM, Modul 23
Research
- Immunopathology, treatment and outcome of ANCA-associated vasculitides.
- Diagnosis, treatment and outcome of thrombotic microangiopathies (TTP, aHUS).
- Use of cystatin C in clinical practice. Role of cystatin C in fibrosis.
- Cooperation within the European Vasculitis Society (EUVAS), the German Vasculitis Registry (GeVas) and the RITERM study group.
Other activities
Publications
Recent publications
Article
Seiberth S, Bauer D, Schönermarck U, Mannell H, Stief C, Hasford J, Strobach D. Implementation of a renal pharmacist consultant service - Information sharing in paper versus digital form. J Clin Pharm Ther. 2021 Feb 20. doi: 10.1111/jcpt.13371.
Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med. 2021 Feb 18;384(7):599-609. doi: 10.1056/NEJMoa2023386.
Habler K, Brügel M, Teupser D, Liebchen U, Scharf C, Schönermarck U, Vogeser M, Paal M. Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum. J Pharm Biomed Anal. 2021 Mar 20;196:113935. doi: 10.1016/j.jpba.2021.113935.
Schönermarck U, Kemmner S, Fischereder M. Belimumab in Lupus Nephritis. N Engl J Med. 2021 Jan 14;384(2):187-188. doi: 10.1056/NEJMc2032520.
Gäckler A, Schönermarck U, Dobronravov V, La Manna G, Denker A, Liu P, Vinogradova M, Yoon SS, Praga M. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. BMC Nephrol. 2021 Jan 6;22(1):5. doi: 10.1186/s12882-020-02190-0.
Lean I, Paal M, Suttmann Y, Dengler C, Schönermarck U. Comment on: 'Effects of dose and type of corticosteroids on the divergence between estimated glomerular filtration rates derived from cystatin C and creatinine' by Tsushita et al. J Clin Pharm Ther. 2020 Dec 16. doi: 10.1111/jcpt.13332.
Schüttler D, Schönermarck U, Wenner F, Toepfer M, Rizas KD, Bauer A, Brunner S, Hamm W. Large potassium shifts during dialysis enhance cardiac repolarization instability. J Nephrol. 2020 Oct 15. doi: 10.1007/s40620-020-00880-4.
Grigorescu M, Kamla CE, Wassilowsky D, Joskowiak D, Peterss S, Kemmner S, Pichlmaier M, Hagl C, Fischereder M, Schönermarck U. Severe Acute Kidney Injury in Cardiovascular Surgery: Thrombotic Microangiopathy as a Differential Diagnosis to Ischemia Reperfusion Injury. A Retrospective Study. J Clin Med. 2020 Sep 8;9(9):2900. doi: 10.3390/jcm9092900.
Seiberth S, Bauer D, Schönermarck U, Mannell H, Stief C, Hasford J, Strobach D. Correct use of non-indexed eGFR for drug dosing and renal drug-related problems at hospital admission. Eur J Clin Pharmacol. 2020 Dec;76(12):1683-1693. doi: 10.1007/s00228-020-02953-6. Epub 2020 Jul 10.
Schönermarck U, Dengler C, Lean I, Waldmann E. Comment on: "Overestimation of glomerular filtration rate calculated from serum creatinine as compared with cystatin C in patients with subclinical hypercortisolism: Hyogo Adrenal Metabolic Registry" by Naka et al. Endocr J. 2020 Aug 28;67(8):889-890. doi: 10.1507/endocrj.EJ20-0321.
Schönermarck U, Hentrich M, Bassermann F, Theurich S, Fischereder M. [Onconephrology - Interdisciplinary Cooperation of Nephrologists and Oncologists in the Treatment of Multiple Myeloma]. Dtsch Med Wochenschr. 2020 Jun;145(12):828-835. doi: 10.1055/a-1010-8623.
Kemmner S, Guba MO, Schönermarck U, Stangl M, Fischereder M. Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection. Kidney Int. 2020 Aug;98(2):507-508. doi: 10.1016/j.kint.2020.05.024.
Schönermarck U, Suttmann Y, Fischereder M. Soluble Urokinase Receptor and Acute Kidney Injury. N Engl J Med. 2020 May 28;382(22):2166. doi: 10.1056/NEJMc2003613.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2020 Jun;97(6):1287-1296. doi: 10.1016/j.kint.2020.01.035.
Schönermarck U, Ries W, Schröppel B, Pape L, Dunaj-Kazmierowska M, Burst V, Mitzner S, Basara N, Starck M, Schmidbauer D, Mellmann A, Dittmer R, Jeglitsch M, Haas CS. Relative incidence of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in clinically suspected cases of thrombotic microangiopathy. Clin Kidney J. 2019 Jun 18;13(2):208-216. doi: 10.1093/ckj/sfz066. eCollection 2020 Apr.
Miesbach W, Menne J, Bommer M, Schönermarck U, Feldkamp T, Nitschke M, Westhoff TH, Seibert FS, Woitas R, Sousa R, Wolf M, Walzer S, Schwander B. Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study. Orphanet J Rare Dis. 2019 Nov 15;14(1):260. doi: 10.1186/s13023-019-1240-0.
Sagmeister MS, Grigorescu M, Schönermarck U. Kidney transplantation in ANCA-associated vasculitis. J Nephrol. 2019 Dec;32(6):919-926. doi: 10.1007/s40620-019-00642-x.
